## Abstract Auto‐antibodies to myocardial antigens have been implicated in the pathogenesis of chronic dilated cardiomyopathy (DCM). A protein A immunoadsorption affinity column system was used to remove IgG antibodies, particularly IgG3. Two techniques, the standard technique (T‐1) used for remova
A pilot study to assess the use of protein a immunoadsorption for chronic dilated cardiomyopathy
✍ Scribed by Leslie T. Cooper; Marek Belohlavek; Josef Korinek; Shiro Yoshifuku; Partho P. Sengupta; Edwin A. Burgstaler; Jeffrey L. Winters
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 135 KB
- Volume
- 22
- Category
- Article
- ISSN
- 0733-2459
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Dilated cardiomyopathy (DCM) is a leading cause of end‐stage heart failure and cardiac transplantation. Anticardiac antibodies are common and removal of these through immunoadsorption (IA) is associated with improvement in global cardiac function. The effect of IA on regional function and quality of life (QOL) without intravenous immunoglobulin (IVIG) substitution has not been described. We performed a pilot trial using Immunosorba® columns in four patients with chronic DCM and NYHA Class II–III congestive heart failure. Subjects were followed for 6 months with serial echocardiograms and validated QOL assessments. Regional and global left ventricular (LV) end‐systolic deformations were assessed by two‐dimensional strain echocardiography. Total IgG decreased 95% (from 1,210 ± 274 mg/dl to 57 ± 16 mg/dl, P = 0.003) and IgG3 decreased 61% (from 33 ± 16 mg/dl to 13 ± 7 mg/dl, P = 0.024). QOL improved from baseline to 6 months as assessed by the Living with Heart Failure questionnaire (from 54 ± 18 to 19 ± 7, P = 0.029). Mean LV ejection fraction improved from 35 to 40% at Day 5 and to 44% at 6 months (P = NS). The LV end diastolic and end systolic volumes decreased (220–202 ml, 159–130 ml, P = NS) at 6 months. Global end‐systolic strain improved from −7.3% at baseline to −8.5% at Day 5 and −8.8% at 6 months (P = NS). Regional LV function and response to IA was not uniform. Even without IVIG substitution, IA for the treatment of chronic DCM is associated with improved QOL up to 6 months after treatment. A randomized, sham‐controlled trial is required to confirm the benefits of IA for DCM. J. Clin. Apheresis., 2007 © 2007 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract ## Objective To evaluate the efficacy of a herbal medicine (Mao‐to) on psychiatric complications caused by IFN, and to examine the relationship between depression and microcirculation. ## Methods Twelve patients with chronic hepatitis C and a past history of IFN‐induced depression we
## Objective: The 2-[(18)f]-fluoro-2-deoxy-d-glucose-positron emission tomography (fdg-pet) technique provides information on uptake and metabolism of glucose in various tissues. compared with resting cells, activated lymphocytes take up radioactively labeled glucose analog at a higher rate, which
## Abstract A head exposure setup for efficient and precisely defined exposure of human subjects equipped with a near‐infrared imaging (NIRI) sensor is presented. In a partially shielded anechoic chamber the subjects were exposed to Universal Mobile Telecommunications System (UMTS)‐like electromagn